Avivia BV, a Dutch based pharmaceutical contract research organization company, is pleased to announce that Gert Jan Ettema will become the new Managing Director of Avivia. Gert Jan succeeds Hans Platteeuw, founder of Avivia, who will take a seat as a member of the Supervisory Board.
Gert Jan will lead the company into the next phase by expanding and strengthening the contract R&D activities with a results driven focus on creating value for Avivia’s partners.
Hans Platteeuw: “After 17 years of hard work and providing all my knowledge and expertise at Avivia to customers, time has come to step aside and hand over the business. Gert Jan has gained a wealth of knowledge in developing new drug products, generics and value-added medicines over the past 28 years when employed as organic chemist, project manager & portfolio manager at Synthon, MSD and Chemconnection. The combination of his broad technical and management experience and his passion for development of new and value-added medicines make him the ideal next Managing Director for Avivia.
Gert Jan Ettema: “There is a clear market need for experienced, pragmatic, result-driven and scientifically sound development capacity to create save and effective dosage forms for new and repurposed drugs. I am proud to be part of Avivia’s experienced team in supporting companies in the challenging but very exciting environment of drug product development”.
